FDA rejects Defender motion sickness gel
31 Jan 2024
Drug ApprovalNDA
St. Louis-based Defender Pharmaceuticals revealed that the U.S. FDA issued a complete response letter in response to the company’s NDA for intranasal scopolamine for the prevention of nausea and vomiting induced by motion.
While Defender did not share the reasons why the agency rejected the application, the company said it plans to schedule a formal meeting with the FDA to fully understand the issues raised in the CRL and implement an action plan.
Scopolamine has been approved for decades as a transdermal system for the treatment of motion sickness and postoperative nausea/vomiting. According to Defender, when administered as an intranasal gel, scopolamine demonstrated rapid absorption, which means the formulation could potentially bring relief faster.
The intranasal gel, Defender's lead program, is intended for specific military personnel and astronauts.
The company has been working with the U.S. Naval Medical Research Unit and NASA on the development.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.